Cryoport, Inc. (NASDAQ: CYRX) announced that its IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support two clinical-stage CAR T cell therapy programs.

Verismo, a subsidiary of HLB Innovation, is developing a multi-chain KIR-CAR platform for the treatment of solid tumors and B cell-associated disorders. Its two lead candidates, SynKIR-110 and SynKIR-310, are currently being evaluated in separate Phase 1 clinical trials. Initial Phase 1 data for both candidates were presented at the American Association for Cancer Research Annual Meeting in 2026.

SynKIR-110 is being evaluated in the STAR-101 Phase 1 trial in patients with advanced mesothelin-expressing solid tumors. SynKIR-310 is being evaluated in the CELESTIAL-301 Phase 1 trial in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

According to the press release, IntegriCell will provide process development, technology transfer, and clinical cryopreservation services. Cryoport said IntegriCell implemented Verismo's existing proprietary cryopreservation process within its GMP-compliant quality management system.

"By implementing Verismo's existing proprietary cryopreservation process within our global quality management system, we enabled them to preserve their existing regulatory work while gaining the consistency and reliability of our bioprocessing, cryopreservation and distribution infrastructure," said Mark Sawicki, CEO of Cryoport Systems.

Bryan Kim, CEO and Co-Founder of Verismo Therapeutics, said the IntegriCell team "implemented our process with precision and worked alongside us to identify opportunities to improve process control and long-term scalability."

IntegriCell operates cryopreservation service centers in Houston, Texas and Liège, Belgium. The service integrates with Cryoport Systems' broader temperature-controlled supply chain platform, which includes biologistics, biostorage, and informatics capabilities.